{"id":598,"date":"2025-05-13T11:40:34","date_gmt":"2025-05-13T09:40:34","guid":{"rendered":"https:\/\/studienportal-gyn.de\/no-effect-on-ovarian-cancer-development-of-nemvaleukin-is-stopped\/"},"modified":"2026-03-05T16:49:15","modified_gmt":"2026-03-05T15:49:15","slug":"no-effect-on-ovarian-cancer-development-of-nemvaleukin-is-stopped","status":"publish","type":"post","link":"https:\/\/studienportal-gyn.de\/en\/no-effect-on-ovarian-cancer-development-of-nemvaleukin-is-stopped\/","title":{"rendered":"No effect on ovarian cancer: development of Nemvaleukin is stopped"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

No effect on ovarian cancer: <\/strong>
Development of Nemvaleukin is stopped<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

In March 2025, Mural Oncology released disappointing news for patients with platinum-resistant ovarian cancer<\/strong>.<\/p>

The international phase 3 ARTISTRY-7 trial investigated whether a combination of two immunotherapies – nemvaleukin<\/strong> and pembrolizumab<\/strong> – is more effective than standard chemotherapy. Unfortunately, an interim analysis showed that the combination therapy did not prolong patient survival compared to chemotherapy. <\/p>

The mean survival time was 10.1 months in the immunotherapy group and 9.8 months in the comparison group – a very small and therefore not statistically relevant difference. The study was therefore stopped prematurely and the development of the drug for this form of cancer was discontinued. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

What is Nemvaleukin?<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Nemvaleukin<\/strong> is an experimental drug that was originally developed to specifically activate the immune system against tumor cells – without the strong side effects of conventional immune activators. It has already been tested in several studies, including in black skin cancer (melanoma). There, too, the hoped-for therapeutic successes failed to materialize. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Consequences: Company discontinues development<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A few weeks after the initial results, Mural Oncology announced that it would discontinue all clinical development of Nemvaleukin<\/strong> – including for other types of cancer such as melanoma. At the same time, the company is planning a drastic restructuring in terms of job cuts and possibly a sale or merger with another company. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Significance for patients<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

For patients with platinum-resistant ovarian cancer, treatment remains a major challenge – new options are urgently needed. Despite this disappointment, the study is an important contribution to a better understanding of why some cancers, such as ovarian cancer, respond so poorly to immunotherapies. <\/p>

Source:<\/strong> Mural Oncology press release 1<\/a> and press release 2<\/a> (the articles are in English)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

No effect on ovarian cancer: Development of Nemvaleukin is stopped In March 2025, Mural Oncology released disappointing news for patients with platinum-resistant ovarian cancer. The international phase 3 ARTISTRY-7 trial investigated whether a combination of two immunotherapies – nemvaleukin and pembrolizumab – is more effective than standard chemotherapy. Unfortunately, an interim analysis showed that the […]<\/p>\n","protected":false},"author":3,"featured_media":599,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,55,54],"tags":[59,60,61,56],"class_list":["post-598","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-science","category-studies","tag-artistry7","tag-mural-oncology","tag-nemvaleukin","tag-ovarian-cancer"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/posts\/598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/comments?post=598"}],"version-history":[{"count":1,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/posts\/598\/revisions"}],"predecessor-version":[{"id":600,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/posts\/598\/revisions\/600"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/media\/599"}],"wp:attachment":[{"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/media?parent=598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/categories?post=598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/tags?post=598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}